Neurocrine Biosciences
NBIX
#1578
Rank
NZ$22.82 B
Marketcap
NZ$228.93
Share price
1.15%
Change (1 day)
-15.05%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): NZ$7.40

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is NZ$7.17. In 2024 the company made an earnings per share (EPS) of NZ$5.62 an increase over its 2023 EPS that were of NZ$4.23.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$7.4031.57%
2024NZ$5.6233.07%
2023NZ$4.2357.76%
2022NZ$2.6869.47%
2021NZ$1.58-78.21%
2020NZ$7.25990%
2019NZ$0.6781.82%
2018NZ$0.37-113.5%
2017NZ-$2.710.62%
2016NZ-$2.6957.28%
2015NZ-$1.7125.61%
2014NZ-$1.3618.84%
2013NZ-$1.15-1085.71%
2012NZ$0.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.86-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$2.25-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$34.13 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$0.04990-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ-$3.38-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$2.84-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ-$49.74-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$2.94-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK